Site search
2807 results for '' found
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 via an Implantable Pump and a Cranial Port and Double Lumen Catheter (CIC)
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 via an Implantable Pump and a Cranial Port and Double Lumen Catheter (CIC)
/
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36, for Intratumoral Injection Alone and in Co
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36, for Intratumoral Injection Alone and in Co
/
A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants with High-Risk Multiple Myeloma (MonumenTAL-8) (NCT06550895)
A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants with High-Risk Multiple Myeloma (MonumenTAL-8) (NCT06550895)
/
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participant
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participant
/
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma (NCT05050097)
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma (NCT05050097)
/
Multi-Organ Denervation to RedUce Sympathetic Drive, A Single Blinded, Multi-Center, Prospective Feasibility Study (MODUS Study) (ACTRN12620000412932)
Multi-Organ Denervation to RedUce Sympathetic Drive, A Single Blinded, Multi-Center, Prospective Feasibility Study (MODUS Study) (ACTRN12620000412932)
/
A Multi-centre, Phase 1/2, Randomised, Double-blind, Placebo-controlled Study with an Optional Open-label Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of PLL001
A Multi-centre, Phase 1/2, Randomised, Double-blind, Placebo-controlled Study with an Optional Open-label Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of PLL001
/
Phase 2 Study of ISL+ULO QW in Virologically Suppressed Adults With HIV-1 (NCT06891066)
Phase 2 Study of ISL+ULO QW in Virologically Suppressed Adults With HIV-1 (NCT06891066)
/
A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors (NCT06460961)
A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors (NCT06460961)
/
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (NCT06036836)
A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (NCT06036836)
/